Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2020

June 2020 | 282 pages | ID: CB670EE1B78EN
Global Markets Direct

Abstracts

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia - Pipeline Review, H1 2020, provides an overview of the Cervical Intraepithelial Neoplasia (Women's Health) pipeline landscape.
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Intraepithelial Neoplasia (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 15, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 2 and 4 molecules, respectively.
Cervical Intraepithelial Neoplasia (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (Women's Health).
• The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (Women's Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cervical Intraepithelial Neoplasia (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (Women's Health)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (Women's Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (Women's Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Altum Pharmaceuticals Inc, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Antiva Biosciences Inc, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Brooklyn ImmunoTherapeutics LLC, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Douglas Pharmaceuticals Ltd, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Elicio Therapeutics, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by GenoLac BL Corp, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Gilead Sciences Inc, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2020
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Altum Pharmaceuticals Inc
Antiva Biosciences Inc
Beijing Kangle Guardian Biotechnology Co Ltd
Bioleaders Corp
Brooklyn ImmunoTherapeutics LLC
CEL-SCI Corp
Douglas Pharmaceuticals Ltd
Elicio Therapeutics
Genexine Inc
GenoLac BL Corp
Gilead Sciences Inc
Hefei Ruichengsheng Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
KinoPharma Inc
Merck & Co Inc
Novan Inc
Papivax LLC
PDS Biotechnology Corp
Redbiotec AG
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Institute of Biological Products Co Ltd
THEVAX Genetics Vaccine USA Inc
Transgene SA
Vaccibody AS
ViciniVax BV